Travere Therapeutics Inc. (TVTX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Travere Therapeutics, Inc. (TVTX) Presents at Cantor Global Healthcare Conference 2025 Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Cantor Global Healthcare Conference 2025 September 4, 2025 2:45 PM EDT Company Participants Eric Dube - President, CEO & Director Peter Heerma - Chief Commercial Officer Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Hello, everyone.
Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Christopher Cline - Chief Financial Officer Eric M. Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Nivi Nehra - Corporate Participant e - Corporate Participant V - Corporate Participant i - Corporate Participant c - Corporate Participant P - Corporate Participant r - Corporate Participant e - Corporate Participant s - Corporate Participant i - Corporate Participant d - Corporate Participant Communications & Investor Relations - Corporate Participant e - Corporate Participant n - Corporate Participant t - Corporate Participant o - Corporate Participant f - Corporate Participant o - Corporate Participant r - Corporate Participant p - Corporate Participant o - Corporate Participant r - Corporate Participant a - Corporate Participant t - Corporate Participant e - Corporate Participant Peter Heerma - Chief Commercial Officer William E.
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.9 per share a year ago.
Travere Therapeutics: Establishing A Position After Last Week's Selloff
Travere Therapeutics focuses on rare kidney and metabolic diseases, with strong revenue growth from recently approved Filspari and a narrowing loss in Q1 2024. Analysts generally remain bullish, with multiple Buy ratings and price targets ranging from $22 to $45 a share on the stock that current trades around $17.00 a share. The company did suffer a bit of setback last week as the FDA moved back the anticipated decision date on a recently submitted sNDA.
Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO William Rote - Senior Vice President of Research & Development Conference Call Participants Tyler Van Buren - TD Cowen Vamil Davin - Guggenheim Anupam Rama - JPMorgan Laura Chico - Wedbush Securities Liisa Bayko - Evercore Greg Harrison - Scotiabank Maury Raycroft - Jefferies Prakhar Agrawal - Cantor Jason Zemansky - Bank of America Operator Good afternoon, and welcome to the Travere Therapeutics First Quarter and Full Year 2025 Financial Results Conference Call. Today's call is being recorded.
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $1.76 per share a year ago.
Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO William Rote - Senior Vice President of Research & Development Conference Call Participants Malcolm Kuno - JPMorgan Vamil Divan - Guggenheim Securities Joseph Schwartz - Leerink Partners Liisa Bayko - Evercore ISI Yigal Nochomovitz - Citigroup Prakhar Agrawal - Cantor Fitzgerald Fadi Ahman - Wells Fargo Gregory Harrison - Scotiabank Jason Zemansky - BofA Securities Alexander Thompson - Stifel Ed Arce - H.C. Wainwright Operator Good afternoon, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
